Holen Sie sich die Stockscreener-App
10.88
0.69%
0.0757
Schlusskurs vom Vortag:
$10.80
Offen:
$10.69
24-Stunden-Volumen:
477.14K
Relative Volume:
0.44
Marktkapitalisierung:
$549.44M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-156.39M
KGV:
-2.9473
EPS:
-3.69
Netto-Cashflow:
$-123.06M
1W Leistung:
-2.29%
1M Leistung:
-8.23%
6M Leistung:
-19.74%
1J Leistung:
-6.49%
1-Tages-Spanne:
$10.51
$11.04
1-Wochen-Bereich:
$10.51
$11.30
52-Wochen-Spanne:
$7.30
$17.28
Kalvista Pharmaceuticals Inc Stock (KALV) Company Profile
Firmenname
Kalvista Pharmaceuticals Inc
Sektor
Branche
Telefon
(857) 999-0075
Adresse
200 CROSSING BOULEVARD, FRAMINGHAM, MA
Vergleichen Sie KALV mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
KALV
Kalvista Pharmaceuticals Inc
|
10.88 | 545.65M | 0 | -156.39M | -123.06M | -3.69 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.53 | 109.22B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
630.36 | 67.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
424.23 | 57.35B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
837.14 | 50.87B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.80 | 39.72B | 447.02M | -1.18B | -868.57M | -6.1812 |
Kalvista Pharmaceuticals Inc Stock (KALV) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-01-31 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2025-01-07 | Eingeleitet | TD Cowen | Buy |
| 2024-12-18 | Eingeleitet | BofA Securities | Buy |
| 2020-06-15 | Eingeleitet | H.C. Wainwright | Buy |
| 2019-07-29 | Eingeleitet | SVB Leerink | Outperform |
| 2019-03-20 | Eingeleitet | Needham | Buy |
| 2018-10-30 | Eingeleitet | Jefferies | Buy |
| 2018-09-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2017-08-31 | Eingeleitet | BTIG Research | Buy |
Alle ansehen
Kalvista Pharmaceuticals Inc Aktie (KALV) Neueste Nachrichten
Exit strategy if you’re trapped in KalVista Pharmaceuticals Inc.2025 Key Lessons & Free Reliable Trade Execution Plans - newser.com
Multi asset correlation models including KalVista Pharmaceuticals Inc.Trade Ideas & Real-Time Price Movement Reports - newser.com
Real time scanner hits for KalVista Pharmaceuticals Inc. explainedWeekly Stock Report & Free High Return Stock Watch Alerts - newser.com
Will KalVista Pharmaceuticals Inc. stock attract more institutional investors2025 Big Picture & Free Safe Capital Growth Stock Tips - newser.com
KalVista Pharmaceuticals to Host Third Quarter Financial Results Conference Call and Webcast on November 11, 2025 - The Joplin Globe
How to track smart money flows in KalVista Pharmaceuticals Inc.Quarterly Portfolio Review & Breakout Confirmation Trade Signals - newser.com
What makes KalVista Pharmaceuticals Inc. stock attractive to growth fundsOil Prices & Verified Swing Trading Watchlist - newser.com
How KalVista Pharmaceuticals Inc. stock performs in high volatility marketsJuly 2025 Analyst Calls & Weekly Chart Analysis and Trade Guides - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock benefit from commodity supercycleJuly 2025 Snapshot & AI Powered Trade Plan Recommendations - newser.com
Why KalVista Pharmaceuticals Inc. (4XC1) stock is favored by hedge fundsQuarterly Growth Report & Weekly Top Performers Watchlists - newser.com
Using R and stats models for KalVista Pharmaceuticals Inc. forecastingJuly 2025 Pullbacks & Weekly Market Pulse Updates - newser.com
Can KalVista Pharmaceuticals Inc. (4XC1) stock sustain margin levelsQuarterly Earnings Summary & Reliable Price Breakout Signals - newser.com
Is KalVista Pharmaceuticals Inc. (4XC1) stock a defensive play amid uncertaintyTrade Entry Report & High Conviction Trade Alerts - newser.com
Will KalVista Pharmaceuticals Inc. stock reach Wall Street targetsCPI Data & Weekly Breakout Watchlists - newser.com
What market sentiment indicators show for KalVista Pharmaceuticals Inc. (4XC1) stockProduct Launch & Fast Momentum Entry Tips - newser.com
How strong is KalVista Pharmaceuticals Inc. (4XC1) stock earnings growthJuly 2025 PostEarnings & Step-by-Step Swing Trade Plans - newser.com
KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Receives Average Recommendation of "Moderate Buy" from Brokerages - MarketBeat
Will a bounce in KalVista Pharmaceuticals Inc. offer an exit2025 Support & Resistance & Daily Oversold Bounce Ideas - newser.com
How hedge fund analytics apply to KalVista Pharmaceuticals Inc. stockM&A Rumor & AI Driven Price Forecasts - newser.com
Will KalVista Pharmaceuticals Inc. (4XC1) stock keep high P E multiplesJuly 2025 Catalysts & Safe Entry Momentum Stock Tips - newser.com
KalVista, Ionis/Sobi among latest to win EU nod for rare disease drugs - MSN
Emerald Mutual Fund Advisers Trust Increases Stake in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
Emerald Advisers LLC Boosts Stock Position in KalVista Pharmaceuticals, Inc. $KALV - MarketBeat
KalVista Pharmaceuticals (NASDAQ:KALV) Shares Pass Below Fifty Day Moving AverageWhat's Next? - MarketBeat
KalVista Pharmaceuticals to Present New EKTERLY® (sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - The Joplin Globe
(sebetralstat) Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting - Business Wire
Finanzdaten der Kalvista Pharmaceuticals Inc-Aktie (KALV)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.13%
0.49%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):